Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 38.0%

Posted by Amanda Harley on Mar 16th, 2025

Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 36,300 shares, a growth of 38.0% from the February 13th total of 26,300 shares. Based on an average daily volume of 98,300 shares, the short-interest ratio is presently 0.4 days. Approximately 1.9% of the shares of the company are short sold.

Analysts Set New Price Targets

Several research firms recently weighed in on THAR. Rodman & Renshaw started coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a report on Friday, December 6th.

Check Out Our Latest Analysis on Tharimmune

Hedge Funds Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC acquired a new stake in Tharimmune, Inc. (NASDAQ:THAR – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune at the end of the most recent quarter. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Price Performance

Tharimmune stock remained flat at $1.45 during trading hours on Friday. The company’s stock had a trading volume of 9,370 shares, compared to its average volume of 351,487. The company’s fifty day simple moving average is $1.85 and its 200-day simple moving average is $2.20. Tharimmune has a 12-month low of $1.28 and a 12-month high of $7.46.

Tharimmune Company Profile

(Get Free Report)

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).